

By: Senator(s) Younger, Gollott, Jolly,
Seymour, Jordan, Chassaniol, Bryan, Turner-
Ford

To: Drug Policy; Judiciary,
Division A

SENATE BILL NO. 2475

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972,
2 TO ADD KRATOM TO THE LIST OF SCHEDULE I CONTROLLED SUBSTANCES; AND
3 FOR RELATED PURPOSES.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

5 **SECTION 1.** Section 41-29-113, Mississippi Code of 1972, is
6 amended as follows:

7 41-29-113. The controlled substances listed in this section
8 are included in Schedule I.

9 **SCHEDULE I**

10 (a) **Opiates.** Any of the following opiates, including their
11 isomers, esters, ethers, salts and salts of isomers, esters and
12 ethers, unless specifically excepted, whenever the existence of
13 these isomers, esters, ethers and salts is possible within the
14 specific chemical designation:

15 (1) Acetyl-alpha-methylfentanyl;

16 (2) Acetyl Fentanyl

17 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide;

18 (3) Acetylmethadol;



19 (4) Allylprodine;
20 (5) Alphacetylmethadol, except levo-alphacetylmethadol
21 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);
22 (6) Alphameprodine;
23 (7) Alphamethadol;
24 (8) Alpha-methylfentanyl;
25 (9) Alpha-methylthiofentanyl;
26 (10) Benzethidine;
27 (11) Betacetylmethadol;
28 (12) Beta-hydroxyfentanyl;
29 (13) Beta-hydroxy-3-methylfentanyl;
30 (14) Betameprodine;
31 (15) Betamethadol;
32 (16) Betaprodine;
33 (17) Clonitazene;
34 (18) Dextromoramide;
35 (19) Diampromide;
36 (20) Diethylthiambutene;
37 (21) Difenoxin;
38 (22) Dimenoxadol;
39 (23) Dimepheptanol;
40 (24) Dimethylthiambutene;
41 (25) Dioxaphetyl butyrate;
42 (26) Dipipanone;
43 (27) Ethylmethylthiambutene;



44 (28) Etonitazene;
45 (29) Etoxeridine;
46 (30) Furethidine;
47 (31) Hydroxypethidine;
48 (32) Ketobemidone;
49 (33) Levomoramide;
50 (34) Levophenacylmorphane;
51 (35) 3-methylfentanyl;
52 (36) 3-methylthiofentanyl;
53 (37) Morpheridine;
54 (38) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
55 (39) Noracymethadol;
56 (40) Norlevorphanol;
57 (41) Normethadone;
58 (42) Norpipanone;
59 (43) Para-fluorofentanyl;
60 (44) PEPAP
61 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
62 (45) Phenadoxone;
63 (46) Phenampromide;
64 (47) Phenomorphan;
65 (48) Phenoperidine;
66 (49) Piritramide;
67 (50) Proheptazine;
68 (51) Properidine;



- 69 (52) Propiram;
70 (53) Racemoramide;
71 (54) Thiofentanyl;
72 (55) Tilidine;
73 (56) Trimeperidine.

74 (b) **Opiate derivatives.** Any of the following opium
75 derivatives, their salts, isomers and salts of isomers, unless
76 specifically excepted, whenever the existence of these salts,
77 isomers and salts of isomers is possible within the specific
78 chemical designation:

- 79 (1) Acetorphine;
80 (2) Acetyldihydrocodeine;
81 (3) Benzylmorphine;
82 (4) Codeine methylbromide;
83 (5) Codeine-N-Oxide;
84 (6) Cyprenorphine;
85 (7) Desomorphine;
86 (8) Dihydromorphine;
87 (9) Drotebanol;
88 (10) Etorphine; (except hydrochloride salt);
89 (11) Heroin;
90 (12) Hydromorphenol;
91 (13) Methyldesorphine;
92 (14) Methyldihydromorphine;
93 (15) Monoacetylmorphine;



- 94 (16) Morphine methylbromide;
95 (17) Morphine methylsulfonate;
96 (18) Morphine-N-Oxide;
97 (19) Myrophine;
98 (20) Nicocodeine;
99 (21) Nicomorphine;
100 (22) Normorphine;
101 (23) Pholcodine;
102 (24) Thebacon.

103 (c) **Hallucinogenic substances.** Any material, compound,
104 mixture or preparation which contains any quantity of the
105 following substances, their salts, isomers (whether optical,
106 positional, or geometric) and salts of isomers, unless
107 specifically excepted, whenever the existence of these salts,
108 isomers and salts of isomers is possible within the specific
109 chemical designation:

- 110 (1) Alpha-ethyltryptamine;
111 (2) 4-bromo-2,5-dimethoxy-amphetamine;
112 (3) 4-bromo-2,5-dimethoxyphenethylamine;
113 (4) 2,5-dimethoxyamphetamine;
114 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
115 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine
116 (2C-T-7);
117 (7) 4-methoxyamphetamine;
118 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;



- 119 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 120 (10) 3,4-methylenedioxy amphetamine;
- 121 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 122 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known
- 123 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl
- 124 MDA, MDE, MDEA);
- 125 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also
- 126 known as N-hydroxy MDA, N-OHMDA, and
- 127 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine);
- 128 (14) 3,4,5-trimethoxy amphetamine;
- 129 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 130 (16) Alpha-methyltryptamine (also known as AMT);
- 131 (17) Bufotenine;
- 132 (18) Diethyltryptamine;
- 133 (19) Dimethyltryptamine;
- 134 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 135 (21) Ibogaine;
- 136 (22) Lysergic acid diethylamide (LSD);
- 137 (23) (A) Marijuana;
- 138 (B) Hashish;
- 139 (24) Mescaline;
- 140 (25) Parahexyl;
- 141 (26) Peyote;
- 142 (27) N-ethyl-3-piperidyl benzilate;
- 143 (28) N-methyl-3-piperidyl benzilate;



144 (29) Psilocybin;
145 (30) Psilocyn;
146 (31) Tetrahydrocannabinols, meaning
147 tetrahydrocannabinols contained in a plant of the genus Cannabis
148 (cannabis plant), as well as the synthetic equivalents of the
149 substances contained in the cannabis plant, or in the resinous
150 extractives of such plant, and/or synthetic substances,
151 derivatives, and their isomers with similar chemical structure and
152 pharmacological activity to those substances contained in the
153 plant such as the following:

- 154 (A) 1 cis or trans tetrahydrocannabinol;
155 (B) 6 cis or trans tetrahydrocannabinol;
156 (C) 3,4 cis or trans tetrahydrocannabinol.

157 (Since nomenclature of these substances is not
158 internationally standardized, compounds of these structures,
159 regardless of atomic positions are covered.)

160 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)

161 However, the following products are exempted from control:

- 162 (i) THC-containing industrial products made
163 from cannabis stalks (e.g., paper, rope and clothing);
164 (ii) Processed cannabis plant materials used
165 for industrial purposes, such as fiber retted from cannabis stalks
166 for use in manufacturing textiles or rope;
167 (iii) Animal feed mixtures that contain
168 sterilized cannabis seeds and other ingredients (not derived from



the cannabis plant) in a formula designed, marketed and distributed for nonhuman consumption;

(iv) Personal care products that contain oil from sterilized cannabis seeds, such as shampoos, soaps, and body lotions (if the products do not cause THC to enter the human body); and

(v) Processed cannabis plant extract, oil or resin with a minimum ratio of twenty-to-one cannabidiol to tetrahydrocannabinol (20:1 cannabidiol:tetrahydrocannabinol), and diluted so as to contain at least fifty (50) milligrams of cannabidiol per milliliter, with not more than two and one-half (2.5) milligrams of tetrahydrocannabinol per milliliter;

(32) Phencyclidine;

(33) Ethylamine analog of phencyclidine (PCE);

(34) Pyrrolidine analog of phencyclidine (PHP, PCPy);

(35) Thiophene analog of phencyclidine;

(36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy);

(37) 4-methylmethcathinone (mephedrone);

(38) 3,4-methylenedioxypyrovalerone (MDPV);

(39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);

(40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);

(41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

(42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

or 2,5-dimethoxy-4-iodophenethylamine;



193 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine
194 (2C-T-2);
195 (44)
196 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
197 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H);
198 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
199 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine
200 (2C-P);
201 (48) 3,4-methylenedioxy-N-methylcathinone (methydone);
202 (49)
203 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
204 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
205 (50)
206 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
207 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
208 (51)
209 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or
210 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
211 Cimbi-5);
212 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,
213 4-benzodiazepin-2-one (also known as Phenazepam);
214 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,
215 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene
216 (also known as Etizolam);
217 (54) Salvia divinorum;



(55) Synthetic cannabinoids. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found in any of the following chemical groups, whether or not substituted to any extent, or any of those groups which contain any synthetic cannabinoid salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical designation, including all synthetic cannabinoid chemical analogues in such groups:

(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (also known as HU-210 or 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

(B) Naphthoylindoles and naphthylmethylindoles, being any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted in the indole ring to any extent, or in the naphthyl ring to any extent;

(C) Naphthoylpyrroles, being any compound structurally derived from 3-(1-naphthoyl)pyrrole, whether or not substituted in the pyrrole ring to any extent, or in the naphthyl ring to any extent;

(D) Naphthylmethylindenenes, being any compound structurally derived from 1-(1-naphthylmethyl)indene, whether or



243 not substituted in the indene ring to any extent or in the
244 naphthyl ring to any extent;

245 (E) Phenylacetylindoles, being any compound
246 structurally derived from 3-phenylacetylindole, whether or not
247 substituted in the indole ring to any extent or in the phenyl ring
248 to any extent;

249 (F) Cyclohexylphenols, being any compound
250 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether
251 or not substituted in the cyclohexyl ring to any extent or in the
252 phenolic ring to any extent;

253 (G) Benzoylindoles, whether or not substituted in
254 the indole ring to any extent or in the phenyl ring to any extent;

255 (H) Adamantoylindoles, whether or not substituted
256 in the indole ring to any extent or in the adamantoyl ring system
257 to any extent;

258 (I) Tetrahydro derivatives of cannabinal and
259 3-alkyl homologues of cannabinal or of its tetrahydro derivatives,
260 except where contained in cannabis or cannabis resin;

261 (J) 3-Cyclopropylmethanone indole or
262 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by
263 substitution at the nitrogen atom of the indole ring, whether or
264 not further substituted in the indole ring to any extent, whether
265 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl
266 rings to any extent;



267 (K) Quinoliny1 ester indoles, being any compound
268 structurally derived from 1H-indole-3carboxylic acid-8-quinoliny1
269 ester, whether or not substituted in the indole ring to any extent
270 or the quinolone ring to any extent;

271 (L) 3-carboxamide-1H-indazoles, whether or not
272 substituted in the indazole ring to any extent and substituted to
273 any degree on the carboxamide nitrogen and
274 3-carboxamide-1H-indoles, whether or not substituted in the indole
275 ring to any extent and substituted to any degree on the
276 carboxamide nitrogen;

277 (M) Cycloalkanemethanone Indoles, whether or not
278 substituted at the nitrogen atom on the indole ring, whether or
279 not further substituted in the indole ring to any extent, whether
280 or not substituted on the cycloalkane ring to any extent.

281 (d) **Depressants.** Unless specifically excepted or unless
282 listed in another schedule, any material, compound, mixture, or
283 preparation which contains any quantity of the following
284 substances having a depressant effect on the central nervous
285 system, including their salts, isomers, and salts of isomers,
286 whenever the existence of such salts, isomers, and salts of
287 isomers is possible within the specific chemical designation:

288 (1) Gamma-hydroxybutyric acid (other names include:
289 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic
290 acid; sodium oxybate; sodium oxybutyrate);

291 (2) Mecloqualone;



292 (3) Methaqualone.

293 (e) **Stimulants.** Any material, compound, mixture or
294 preparation which contains any quantity of the following central
295 nervous system stimulants including optical salts, isomers and
296 salts of isomers unless specifically excepted or unless listed in
297 another schedule:

298 (1) Aminorex;

299 (2) N-benzylpiperazine (also known as BZP;
300 1-benzylpiperazine);

301 (3) Cathinone;

302 (4) Fenethylamine;

303 (5) Methcathinone;

304 (6) 4-methylaminorex (also known as
305 2-amino-4-methyl-5-phenyl-2-oxazoline);

306 (7) N-ethylamphetamine;

307 (8) Any material, compound, mixture or preparation
308 which contains any quantity of N,N-dimethylamphetamine. (Other
309 names include: N,N,-alpha-trimethyl-benzeneethanamine, and
310 N,N-alpha-trimethylphenethylamine);

311 (9) Unless listed in another schedule, any compound
312 other than bupropion that is structurally derived from
313 2-Amino-1-phenyl-1-propanone by modification in any of the
314 following ways:

315 (i) By substitution in the phenyl ring to any
316 extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide



317 substituents, whether or not further substituted in the phenyl
318 ring by one or more other univalent substituents;

319 (ii) By substitution at the 3-position with an
320 alkyl substituent;

321 (iii) By substitution at the nitrogen atom with
322 alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a
323 cyclic structure.

324 (10) Synthetic cathinones. Unless specifically
325 excepted or unless listed in another schedule, any material
326 compound, mixture or preparation which contains any quantity of a
327 synthetic cathinone found in any of the following compounds,
328 whether or not substituted to any extent, or any of these
329 compounds which contain any synthetic cathinone, or salts,
330 isomers, or salts of isomers, whenever the existence of such
331 salts, isomers or salts of isomers is possible:

332 (i) 4-methyl-N-ethylcathinone ("4-MEC");

333 (ii) 4-methyl-alpha-pyrrolidinopropiophenone
334 ("4-MePPP");

335 (iii) Alpha-pyrrolidinopentiophenone ("α-PVP");

336 (iv)
337 1-(1,3-benzodioxol-5-yl)-2-(methyamino)butan-1-one ("butylone");

338 (v) 2-(methyamino)-1-phenylpentan-1-one
339 ("pentedrone");



340 (vi)
341 1-(1,3-benzodioxol-5-yl)-2-(methyldamino)pentan-1-one
342 ("pentylone");
343 (vii) 4-fluoro-N-methylcathinone ("4-FMC");
344 (viii) 3-fluoro-N-methylcathinone ("3-FMC");
345 (ix)
346 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one ("naphyrone");
347 and
348 (x) Alpha-pyrrolidinobutiophenone ("α-PBP").
349 (11) (i) Mitragynine; and
350 (ii) 7-hydroxymitragynine.

351 **SECTION 2.** This act shall take effect and be in force from
352 and after July 1, 2018.

